Prevents pregnancy. ANDA 76455, held by Duramed Pharms Barr. Desogestrel; Ethinyl Estradiol.
As of Nov 16, 2026, ANDA 76455 (Velivet, Desogestrel; Ethinyl), held by Duramed Pharms Barr, was first approved by FDA on Feb 24, 2004, with 1 approved supplement and 0 published complete response letters.
INDICATIONS AND USAGE Velivet (desogestrel and ethinyl estradiol tablets) is indicated for the prevention of pregnancy in women who elect to use this product as a method of contraception. Oral contraceptives are highly effective. Table 2 lists the typical unintended pregnancy rates for users of combination oral contraceptives and other methods of contraception. The efficacy of these contraceptive methods, except sterilization, the IUD, and implants, depends upon the reliability with which they are used. Correct and consistent use of these methods can result in lower failure rates.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Feb 24, 2004 | Original application | Approved | None posted |
| Velivet0.1MG,0.125MG,0.15MG;0.025MG,0.025MG,0.025MG · tablet;oral-28 | Desogestrel; Ethinyl Estradiol | Rx |
| Desogestrel; Ethinyl0.125MG/0.025MG · tablet; oral | Desogestrel; Ethinyl Estradiol | Rx |
| Desogestrel; Ethinyl0.15MG/0.025MG · tablet; oral | Desogestrel; Ethinyl Estradiol | Rx |
| Jul 14, 2011 | Supplement 11Labeling | Approved | None posted |
| Feb 24, 2004 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters